Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.

Inclusion criteria T1DM <3 months GAD Antibody+ Stimulated C peptide<0.5ng/ml Ketosis at onset Age < 30 yr Exclusion criteria Age > 30 yr Pancreatic disease significant systemic complication

Inclusion Criteria:

• T1DM <3 months
• GAD Antibody+ or Stimulated C peptide<0.5 ng/ml
• Ketosis at onset
• Age < 30 yr

Exclusion Criteria:

• Age > 30 yr
• Pancreas disease
• Significant systemic disease